FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug: Implications for SCD Pipeline and BD Strategy
Decision brief
Answer first · skim in under a minute
Fulcrum Therapeutics is discontinuing its lead sickle cell disease drug, pociredir, after the FDA raised concerns about cancer risk. The decision, which sent shares down 52%, reshapes the SCD competitive landscape and opens strategic questions for pipeline watchers and BD teams.
Fulcrum Therapeutics discontinued pociredir for sickle cell disease on June 1, 2026, after FDA end-of-phase minutes concluded that PRC2-targeted pharmacology carries malignancy risk comparable to withdrawn Tazverik, leaving no viable regulatory path.
Contents8 sections
Key Takeaways
- On May 28, 2026, Fulcrum received FDA meeting minutes raising benefit-risk concerns for pociredir in SCD after secondary hematologic malignancies with Tazverik.
- FDA treated PRC2 complex inhibition as carrying equivalent malignancy risk whether the drug engages EED (pociredir) or EZH2 (tazemetostat).
- Fulcrum announced program discontinuation and a strategic alternatives review on June 1, 2026.
- The company said no new clinical safety signals had been observed with pociredir to date, but saw no path forward despite fetal hemoglobin elevations.
Why did Fulcrum stop pociredir development?
According to Fulcrum’s June 1, 2026 GlobeNewswire release, the company halted its SCD pociredir program after reviewing FDA feedback.
Meeting minutes dated around May 28, 2026, reflected heightened FDA concern about pociredir’s benefit-risk profile after an unexpectedly high rate of secondary hematologic malignancies with Tazverik (tazemetostat), another PRC2 inhibitor withdrawn globally in March 2026.
Fulcrum said it submitted arguments that EED (pociredir’s target) differs mechanistically from EZH2 (tazemetostat’s target). FDA considered that position but concluded any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of subunit engaged.
What regulatory path remains for pociredir?
Fulcrum stated FDA’s position, informed by previously disclosed preclinical malignancy observations for pociredir, left no viable regulatory path for further clinical development in SCD.
CEO Alex C. Sapir said the decision followed discussion with FDA and that, despite strong fetal hemoglobin elevations and potential clinical benefit, the company does not see a path forward.
An SEC Form 8-K filed for the June 1 announcement incorporates the press release as Exhibit 99.1, confirming the disclosure as a material corporate event.
How does this reshape the SCD competitive set?
Removing an oral PRC2-pathway HbF inducer from late clinical contention concentrates attention on approved gene therapies and remaining small-molecule programs with different mechanisms.
For BD teams, Fulcrum’s simultaneous strategic review — covering merger, acquisition, combination, or asset transactions — makes the company a process story as much as a clinical one.
Investors should separate the company’s own statement that no new pociredir clinical safety signals were observed from FDA’s class-level malignancy concern driven by Tazverik’s confirmatory experience.
NCI and NIH educational materials on cell and transplant approaches underscore why SCD pipelines remain strategically important even when one modality exits.
Comparable class-safety shocks in oncology have previously forced pipeline rewrites across an entire target family, not only the withdrawn product. PRC2 inhibition now carries that overhang for any EED- or EZH2-directed SCD or oncology plan still in preclinical stages.
Cash, workforce actions, and remaining preclinical assets will determine whether Fulcrum’s strategic review ends in a sale, a reverse merger, or a slimmed research platform. Those operational details belong in subsequent 8-Ks rather than in the June 1 science narrative alone.
What remains unproven?
Public releases do not quantify an exact secondary malignancy incidence rate for pociredir in humans, because the binding FDA concern is class-level and preclinical, not a newly observed clinical cancer cluster in the Phase 1b SCD cohort.
Stock-move percentages reported in secondary media are not primary FDA facts and should not be treated as company-confirmed without an exchange filing that states them.
Fetal hemoglobin elevations described by Fulcrum as strong are mechanistic proof points, not registrational endpoints. Without a viable FDA path, those biomarker gains do not translate into an approval probability model for pociredir in 2026–2027.
For competitive intelligence teams, the immediate watch list is whether other PRC2-pathway assets disclose FDA meeting outcomes that echo the EED-versus-EZH2 distinction Fulcrum advanced and FDA rejected in May 2026 minutes.
Related NovaPharma coverage
Frequently Asked Questions
Why did the FDA object to pociredir in sickle cell disease?
FDA meeting minutes tied pociredir’s benefit-risk profile to secondary hematologic malignancies seen with Tazverik, another PRC2 inhibitor withdrawn in March 2026, and concluded PRC2-targeted drugs share equivalent malignancy risk.
Did Fulcrum report new clinical cancers on pociredir?
Fulcrum said no new safety signals had been observed to date with pociredir, but FDA’s position plus prior preclinical malignancy observations left no viable SCD regulatory path.
What is Fulcrum doing next?
On June 1, 2026, Fulcrum discontinued pociredir in SCD and started a strategic alternatives review that may include merger, acquisition, or other transactions involving the company or its assets.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for pociredir.
Unlock full calendar →Fulcrum Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
